- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06015737
Eine Studie zur Untersuchung der Wirksamkeit und Sicherheit von Anifrolumab bei Erwachsenen mit chronischem und/oder subakutem kutanem Lupus erythematodes (LAVENDER)
Eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Phase-III-Studie zur Bewertung der Wirksamkeit und Sicherheit von Anifrolumab bei Erwachsenen mit chronischem und/oder subakutem kutanem Lupus erythematodes, die auf eine Antimalariatherapie nicht ansprechen und/oder diese nicht vertragen
This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with chronic and/or subacute cutaneous lupus erythematosus (CLE).
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This is a multicenter, randomized, double-blind, placebo-controlled, Phase III study to evaluate the efficacy and safety of anifrolumab in adults with chronic and/or subacute CLE who are refractory and/or intolerant to antimalarial therapy. The study has a randomized, 24-week double-blind, placebo-controlled study period (Week 0 to Week 23), to evaluate the efficacy and safety of anifrolumab. The double-blind study period will be followed by an open-label, uncontrolled treatment period in which all participants will receive treatment with anifrolumab from Week 24 to Week 51. After the open-label treatment period, participants will enter a 12-week Safety Follow-up Period.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
-
Ciudad de Buenos Aires, Argentinien, 1221
- Research Site
-
Córdoba, Argentinien, 5000
- Research Site
-
Córdoba, Argentinien, X5004BAL
- Research Site
-
Quilmes, Argentinien, 1878
- Research Site
-
San Miguel, Argentinien, 1663
- Research Site
-
-
-
-
-
Kogarah, Australien, 3168
- Research Site
-
Melbourne, Australien, 3004
- Research Site
-
Mitcham, Australien, 3132
- Research Site
-
Westmead, Australien, 2145
- Research Site
-
Woolloongabba, Australien, 04102
- Research Site
-
-
-
-
-
Belo Horizonte, Brasilien, 30150-221
- Research Site
-
Porto Alegre, Brasilien, 90035903
- Research Site
-
Rio de Janeiro, Brasilien, 22470-220
- Research Site
-
Salvador, Brasilien, 40150-150
- Research Site
-
São Paulo, Brasilien, 05403-000
- Research Site
-
-
-
-
-
Sofia, Bulgarien, 1784
- Research Site
-
Sofia, Bulgarien, 1463
- Research Site
-
Sofia, Bulgarien, 1528
- Research Site
-
-
-
-
-
Osorno, Chile, 200025
- Research Site
-
Santiago, Chile, 7500571
- Research Site
-
Santiago, Chile, 130021
- Research Site
-
-
-
-
-
Changchun, China, 130021
- Research Site
-
Changsha, China, 410011
- Research Site
-
Chengdu, China, 610021
- Research Site
-
Chongqing, China, 400016
- Research Site
-
Dongguan, China, 523059
- Research Site
-
Guangzhou, China, 510120
- Research Site
-
Heilongjiang, China, 150086
- Research Site
-
Jinan, China, 250022
- Research Site
-
Shanghai, China, 200025
- Research Site
-
Shanghai, China, 200443
- Research Site
-
Shenzhen, China, 518053
- Research Site
-
Shenzhen, China, 518020
- Research Site
-
Shenzhen, China, 518052
- Research Site
-
Zhuzhou, China, 412007
- Research Site
-
Ürümqi, China, CN-830004
- Research Site
-
-
-
-
-
Berlin, Deutschland, 10117
- Research Site
-
Bochum, Deutschland, 44791
- Research Site
-
Dresden, Deutschland, 01307
- Research Site
-
Erlangen, Deutschland, 91054
- Research Site
-
Essen, Deutschland, 45147
- Research Site
-
Freiburg im Breisgau, Deutschland, 79104
- Research Site
-
Hanover, Deutschland, 30625
- Research Site
-
Kiel, Deutschland, 24105
- Research Site
-
Leipzig, Deutschland, 04103
- Research Site
-
Mainz, Deutschland, 55131
- Research Site
-
Marburg, Deutschland, 35043
- Research Site
-
Regensburg, Deutschland, 93053
- Research Site
-
Wuppertal, Deutschland, 42283
- Research Site
-
-
-
-
-
Aarhus, Dänemark, 641-8510
- Research Site
-
Copenhagen, Dänemark, 2100
- Research Site
-
-
-
-
-
Bois-Guillaume, Frankreich, 76031
- Research Site
-
Dijon, Frankreich, 21000
- Research Site
-
Lyon, Frankreich, 69437
- Research Site
-
Montivilliers, Frankreich, 76290
- Research Site
-
Nantes, Frankreich, 44000
- Research Site
-
Paris, Frankreich, 75010
- Research Site
-
Paris, Frankreich, 75014
- Research Site
-
Paris, Frankreich, 75013
- Research Site
-
Paris, Frankreich, 75970
- Research Site
-
Poitiers, Frankreich, 86000, FR
- Research Site
-
Toulouse, Frankreich, 31059
- Research Site
-
-
-
-
-
Athens, Griechenland, 12462
- Research Site
-
Athens, Griechenland, 16121
- Research Site
-
-
-
-
-
Brescia, Italien, 25123
- Research Site
-
Cona, Italien, 44124
- Research Site
-
Florence, Italien, 50121
- Research Site
-
Milan, Italien, 20132
- Research Site
-
Naples, Italien, 80138
- Research Site
-
Reggio Emilia, Italien, 42123
- Research Site
-
Roma, Italien, 00144
- Research Site
-
Rome, Italien, 00168
- Research Site
-
-
-
-
-
Chūōku, Japan, 104-8560
- Research Site
-
Fukuoka, Japan, 812-8582
- Research Site
-
Kanazawa, Japan, 920-8641
- Research Site
-
Kita-gun, Japan, 761-0793
- Research Site
-
Nagoya, Japan, 457-8510
- Research Site
-
Nagoya, Japan, 467-8602
- Research Site
-
Wakayama, Japan, 641-8510
- Research Site
-
Yokohama, Japan, 232-0024
- Research Site
-
tabashi City, Japan, 173-8606
- Research Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V5Z 1M9
- Research Site
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8N 3Z5
- Research Site
-
Toronto, Ontario, Kanada, M5T 2S8
- Research Site
-
-
-
-
-
Barranquilla, Kolumbien, 080020
- Research Site
-
Bogotá, Kolumbien, 110221
- Research Site
-
-
-
-
-
Guadalajara, Mexiko, 44340
- Research Site
-
Guadalajara, Mexiko, 44610
- Research Site
-
Mexico City, Mexiko, 07760
- Research Site
-
Veracruz, Mexiko, 91910
- Research Site
-
-
-
-
-
Papatoetoe, Neuseeland, 2025
- Research Site
-
-
-
-
-
Breda, Niederlande, 4818 CK
- Research Site
-
Rotterdam, Niederlande, 3015 GD
- Research Site
-
-
-
-
-
Iloilo City, Philippinen, 5000
- Research Site
-
Lipa, Philippinen, 4217
- Research Site
-
Manila, Philippinen, 1000
- Research Site
-
-
-
-
-
Katowice, Polen, 40-851
- Research Site
-
Kielce, Polen, 25-316
- Research Site
-
Ossy, Polen, 40-027
- Research Site
-
Rzeszów, Polen, 35-055
- Research Site
-
Warsaw, Polen, 02-637
- Research Site
-
-
-
-
-
Braga, Portugal, 4710-243
- Research Site
-
Lisbon, Portugal, 1649-035
- Research Site
-
Porto, Portugal, 4099-001
- Research Site
-
-
-
-
-
Bucharest, Rumänien, 020125
- Research Site
-
Iași, Rumänien, 700291
- Research Site
-
-
-
-
-
Belgrade, Serbien, 11000
- Research Site
-
Kragujevac, Serbien, 34000
- Research Site
-
-
-
-
-
Košice, Slowakei, 04001
- Research Site
-
Piešťany, Slowakei, 92101
- Research Site
-
-
-
-
-
Barcelona, Spanien, 8035
- Research Site
-
Barcelona, Spanien, 08025
- Research Site
-
Castellon, Spanien, 12004
- Research Site
-
Granada, Spanien, 18012
- Research Site
-
L'Hospitalet de Llobregat, Spanien, 08907
- Research Site
-
Las Palmas de Gran Canaria, Spanien, 35010
- Research Site
-
Madrid, Spanien, 28034
- Research Site
-
Madrid, Spanien, 28041
- Research Site
-
Madrid, Spanien, 28040
- Research Site
-
Madrid, Spanien, 28006
- Research Site
-
Majadahonda, Spanien, 28222
- Research Site
-
Salamanca, Spanien, 37007
- Research Site
-
Seville, Spanien, 41014
- Research Site
-
Valencia, Spanien, 46014
- Research Site
-
Valencia, Spanien, 46017
- Research Site
-
Vigo, Spanien, 36200
- Research Site
-
-
-
-
-
Cape Town, Südafrika, 7500
- Research Site
-
Johannesburg, Südafrika, 2193
- Research Site
-
-
-
-
-
Seoul, Südkorea, 03080
- Research Site
-
Seoul, Südkorea, 06591
- Research Site
-
Seoul, Südkorea, 06973
- Research Site
-
-
-
-
-
Kaohsiung City, Taiwan, 83301
- Research Site
-
Taichung, Taiwan, 404
- Research Site
-
Taipei, Taiwan, 10449
- Research Site
-
-
-
-
-
Bangkok, Thailand, 10330
- Research Site
-
Bangkok, Thailand, 10700
- Research Site
-
Hat Yai, Thailand, 90110
- Research Site
-
Khlong Luang, Thailand, 12120
- Research Site
-
Khon Kaen, Thailand, 40002
- Research Site
-
-
-
-
-
Cordaleo, Türkei (türkiye), 35575
- Research Site
-
Istanbul, Türkei (türkiye), 34098
- Research Site
-
Kayseri, Türkei (türkiye), 38039
- Research Site
-
Samsun, Türkei (türkiye), 55270
- Research Site
-
-
-
-
Arizona
-
Phoenix, Arizona, Vereinigte Staaten, 85028
- Research Site
-
-
California
-
Covina, California, Vereinigte Staaten, 91722
- Research Site
-
La Jolla, California, Vereinigte Staaten, 92037
- Research Site
-
Los Angeles, California, Vereinigte Staaten, 90045
- Research Site
-
Los Angeles, California, Vereinigte Staaten, 90089
- Research Site
-
Orange, California, Vereinigte Staaten, 92868
- Research Site
-
San Francisco, California, Vereinigte Staaten, 94143
- Research Site
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80045
- Research Site
-
-
Connecticut
-
New Haven, Connecticut, Vereinigte Staaten, 06519
- Research Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20037
- Research Site
-
-
Florida
-
Fort Lauderdale, Florida, Vereinigte Staaten, 33309
- Research Site
-
Miami, Florida, Vereinigte Staaten, 33174
- Research Site
-
Plantation, Florida, Vereinigte Staaten, 33324
- Research Site
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60637
- Research Site
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46202
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21287
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Research Site
-
Boston, Massachusetts, Vereinigte Staaten, 02115-5817
- Research Site
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- Research Site
-
Bloomfield Hills, Michigan, Vereinigte Staaten, 48302
- Research Site
-
-
Minnesota
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68198-5885
- Research Site
-
-
New York
-
New York, New York, Vereinigte Staaten, 10028
- Research Site
-
Rochester, New York, Vereinigte Staaten, 14642
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, Vereinigte Staaten, 28207
- Research Site
-
Statesville, North Carolina, Vereinigte Staaten, 28625
- Research Site
-
-
Ohio
-
Cleveland, Ohio, Vereinigte Staaten, 44195
- Research Site
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97239
- Research Site
-
-
Rhode Island
-
Providence, Rhode Island, Vereinigte Staaten, 02903
- Research Site
-
-
South Carolina
-
Charleston, South Carolina, Vereinigte Staaten, 29425
- Research Site
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten, 75390-8843
- Research Site
-
-
Virginia
-
Charlottesville, Virginia, Vereinigte Staaten, 22903
- Research Site
-
Roanoke, Virginia, Vereinigte Staaten, 24016
- Research Site
-
-
-
-
-
Cambridge, Vereinigtes Königreich, CB2 0QQ
- Research Site
-
Leeds, Vereinigtes Königreich, LS2 9JT
- Research Site
-
London, Vereinigtes Königreich, NW1 2PG
- Research Site
-
London, Vereinigtes Königreich, SE5 9RS
- Research Site
-
London, Vereinigtes Königreich, SE1 7EH
- Research Site
-
London, Vereinigtes Königreich, NW3 2QG
- Research Site
-
Newcastle upon Tyne, Vereinigtes Königreich, NE1 4LP
- Research Site
-
-
-
-
-
Graz, Österreich, 8036
- Research Site
-
Innsbruck, Österreich, 6020
- Research Site
-
Linz, Österreich, 4020
- Research Site
-
Vienna, Österreich, 1130
- Research Site
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Key inclusion criteria:
-
Participants must have a confirmed diagnosis of CLE. Diagnosis must be clinically and histologically confirmed with the following:
- CLASI-A total score ≥ 10 points at Screening and confirmed at randomization.
- Inadequate response or intolerant to antimalarial therapy.
-
Participants should have no medical history or signs or symptoms of active or prior tuberculosis infection (TB) and the same should reflect in chest radiograph or a chest CT scan result.
-
Contraceptive use by males and females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Key exclusion criteria:
- History or evidence of suicidal ideation.
- Severe or life-threatening Systemic lupus erythematosus (SLE).
- Active SLE or Sjögren's Syndrome.
- Any active skin conditions other than CLE that may interfere with the study.
- History of, or current diagnosis of, catastrophic antiphospholipid syndrome (APS).
- History of recurrent infection requiring hospitalization and IV antibiotics.
- COVID-19 infection.
- Any history of an anaphylactic reaction to human proteins, or monoclonal antibodies.
- At screening, if participants do not meet the eligibility criteria assessed based on laboratory test results e.g tests for total bilirubin, serum creatinine etc.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Anifrolumab
Participants will receive anifrolumab as a SC injection from Week 0/Day 1 up to Week 51. |
Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS). |
|
Placebo-Komparator: Placebo
Participants will receive placebo as a SC injection from Week 0/Day 1 up to Week 23. From Week 24 the participants will receive anifrolumab up to and including Week 51. |
Matching placebo solution for injection in aPFS. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of participants with a 70% reduction relative to baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) score
Zeitfenster: At Week 24
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. It consists of 2 separate scores: i) activity of the disease, and ii) measure of damage. The CLASI instrument will be used at each study visit to capture individual skin manifestation scores. CLASI-70 responder (Yes/No) is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. |
At Week 24
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change from baseline in total CLASI-A score
Zeitfenster: At Week 24
|
The CLASI-A is a validated index used for assessing the cutaneous lesions of SLE. |
At Week 24
|
|
Number of participants with CLASI-70 response
Zeitfenster: At Week 12
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. |
At Week 12
|
|
Number of participants with ≥ 7-point reduction from baseline in CLASI-A total score
Zeitfenster: At Week 12
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. A 7-point reduction CLASI-A is established as clinically meaningful improvement in disease for CLE and as being impactful for patients. |
At Week 12
|
|
Number of participants with CLASI-50 response
Zeitfenster: At Week 12 and Week 24
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-50 responder is defined as a responder (yes/no) is defined as a participant who achieves at least a 50% reduction relative to baseline in CLASI-A score. Otherwise, the participant is a non-responder. |
At Week 12 and Week 24
|
|
Number of participants who are sustained CLASI-70 responders
Zeitfenster: Up to Week 52
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. Amongst participants randomized to anifrolumab, the number of participants who maintained a CLASI-70 response from Week 24 up to Week 52 will be evaluated. |
Up to Week 52
|
|
Serum trough (pre-dose) concentrations of anifrolumab
Zeitfenster: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)
|
The Ctrough of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)
|
|
Number of participants with positive antidrug antibody
Zeitfenster: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)
|
The immunogenicity of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)
|
|
Percent change from baseline in suppression of the Interferon 21-gene
Zeitfenster: Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)
|
The pharmacodynamics of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)
|
|
Change from baseline in Skindex-29+3 Symptom domain scores
Zeitfenster: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. The instrument consists of 33 items, which are used to calculate 4 domains: Symptoms (7 items), Emotions (10 items), Functioning (12 items), and Lupus-specific (3 items). The remaining item asks the participants to rate how often they worry about side effects from treatment; however, this item is not used to calculate the domain scores. The response options are on a 5-point verbal rating scale, ranging from 1 (Never) to 5 (All the time). The instrument has a recall period of the previous 4 weeks. Each domain score ranges from 0 to 100 points, with higher scores indicating worse health-related quality of life. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Emotion domain scores
Zeitfenster: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Function domain scores
Zeitfenster: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Lupus-Specific domain scores
Zeitfenster: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Total score
Zeitfenster: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Time from IP start date to CLASI-70 response.
Zeitfenster: From Week 0/Day 1 up to Week 24
|
To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE. |
From Week 0/Day 1 up to Week 24
|
|
Time from IP start date to CLASI-50 response.
Zeitfenster: From Week 0/Day 1 up to Week 24
|
To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE. |
From Week 0/Day 1 up to Week 24
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of participants with adverse events
Zeitfenster: Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)
|
To evaluate the safety and tolerability of anifrolumab compared with placebo in participants with CLE. |
Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- D346BC00001
- 2021-003698-70 (EudraCT-Nummer)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
IPD-Sharing-Zeitrahmen
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD-Sharing-Zugriffskriterien
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .